Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

Aptahem

0.85 SEK

-16.06 %

Less than 1K followers

APTA

Spotlight Stock Market

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
-16.06 %
-18.47 %
-44.85 %
-31.99 %
-39.65 %
-27.99 %
-96.97 %
-99.22 %
-99.83 %

Aptahem operates in the pharmaceutical industry. The company develops aptamer-based drugs for the treatment of acute life-threatening conditions where coagulation and inflammation interact in the disease process. The company's lead candidate is being developed as an emergency drug intended to prevent the onset of life-threatening organ and tissue damage in patients suffering from sepsis. A large part of the research is carried out in collaboration with partners in the industry. The company was founded in 2014 and is headquartered in Malmö.

Read more
Market cap
17.87M SEK
Turnover
13.36K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
12.2
2026

Annual report '25

27.3
2026

General meeting '26

All
Press releases
ShowingAll content types
Regulatory press release12/5/2025, 7:52 AM

Aptahem receives patent protection in China for patent family 2

Aptahem
Press release10/30/2025, 8:56 AM

Aptahem's webinar "Strategic Direction and Planned US Listing" now available

Aptahem
Press release10/22/2025, 10:49 AM

Aptahem Announces English-Language Webinar on Strategic Direction and Planned U.S. Listing

Aptahem

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release10/21/2025, 6:45 AM

Aptahem: Newsletter October 2025

Aptahem
Press release9/25/2025, 1:19 PM

Aptahem moves forward with focus on U.S. listing strategy, regulatory progress, and partner engagement following outcome of rights issue

Aptahem
Regulatory press release9/23/2025, 9:53 AM

Aptahem receives Notice of Allowance in China for patent family 2

Aptahem
Press release9/19/2025, 6:44 AM

Aptahem Outlines Ongoing Preparations for Planned U.S. Listing and Announces Webinar Invitation

Aptahem
Regulatory press release8/27/2025, 2:53 PM

Aptahem is applying to the FDA's CNPV pilot program for accelerated drug review

Aptahem
Press release8/27/2025, 11:33 AM

Aptahem: Newsletter No 2, August 2025

Aptahem
Regulatory press release8/26/2025, 7:21 AM

Aptahem announces Strategic Direction for U.S. Listing to Enable Phase 2 Study and build portfolio assets value

Aptahem
Regulatory press release8/20/2025, 8:07 AM

Aptahem files provisional patent application in USA for new indications for Apta-1

Aptahem
Regulatory press release8/13/2025, 12:13 PM

Aptahem Applies to FDA PreCheck Program - Strategic Step Toward Faster, Higher-Quality Drug Manufacturing

Aptahem
Regulatory press release5/20/2025, 2:20 PM

Aptahem receives strong interest in partnership from a European pharmaceutical company

Aptahem
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.